Imagine spending thousands of dollars on weight-loss medication—only to discover months later that it doesn't work for your ...

The Medicare GLP-1 Bridge may hold the key to Eli Lilly's market share.

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of ...

There is no shortage of headlines about GLP-1 medications. Originally developed to manage blood sugar levels, these medications are now widely known for promoting weight loss. Alongside their rapid ...

A new GLP-1 medication in oral pill form, elecoglipron, could help to significantly reduce blood sugar levels and body weight ...

Medicare's new GLP-1 Bridge program offers eligible beneficiaries Wegovy, Zepbound, or Foundayo for $50 a month starting July ...

MENLO PARK, Calif., June 10, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announces the publication of a landmark ...

Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced that patients can now order the MyPhenome® genetic obesity test directly through ...

One in eight American adults have used a GLP-1 agonist. This class of drugs are prescribed for weight loss, to treat diabetes, and to reduce the risk of heart attack and stroke in adults with heart ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...

Oral GLP-1s are set to shake up the weight-loss drug market, with Foundayo, launched by Eli Lilly in early April, already making waves across the U.S. But given past struggles to meet demand, industry ...